FIELD: medicine; pharmaceuticals.
SUBSTANCE: proposed group of inventions refers to medicine, particularly to neurology. Presented is a method for preventing or reducing a migraine headache in a patient and a method for preventive treatment of a migraine patient, comprising administering to a patient an anti-CGRP receptor antibody or antigen-binding fragment thereof in dose of 35 mg to 210 mg once a month. Pre-filled autoinjector or syringe for preventive treatment of migraine, including a pharmaceutical composition containing 70 or 140 mg of CGRP receptor antibody, acetate buffer, saccharose and polysorbate.
EFFECT: presented group of inventions provides effective reduction of the frequency, severity and/or duration of migraine headache in the patients having indications for this purpose without any or with minimal undesirable side effects.
28 cl, 9 dwg, 11 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF TREATING VISCERAL PAIN BY ADMINISTERING ANTAGONIST ANTIBODIES AGAINST CALCITONIN GENE-RELATED PEPTIDE | 2010 |
|
RU2535074C2 |
| SELECTION OF PATIENTS WITH HEADACHE SUSCEPTIBLE TO ANTIBODIES AGAINST CALCITONIN GENE-RELATED PEPTIDE | 2018 |
|
RU2770066C2 |
| COMBINED THERAPY FOR CANCER TREATMENT | 2016 |
|
RU2731202C2 |
| METHOD OF TREATING INFLAMMATORY PAIN | 2009 |
|
RU2467765C2 |
| METHODS OF TREATING CHRONIC PAIN | 2009 |
|
RU2522493C2 |
| ANTIBODIES TO PAC1 AND THEIR APPLICATION OPTIONS | 2019 |
|
RU2781553C2 |
| AMHRII BINDING COMPOUNDS FOR PREVENTING OR TREATING CANCER | 2018 |
|
RU2816523C2 |
| COMPOUND BINDING ADRENOMEDULLIN (ADM) FOR USE FOR THERAPY OR PREVENTION OF DISEASE SYMPTOMS | 2018 |
|
RU2790561C2 |
| AMHRII BINDING COMPOUNDS FOR THE PREVENTION OR TREATMENT OF LUNG CANCERS | 2018 |
|
RU2797506C2 |
| MONOCLONAL ANTIBODY AGAINST HUMAN INTERLEUKIN-6 AND HYBRIDOMA PRODUCING THIS MONOCLONAL ANTIBODY | 2014 |
|
RU2550262C1 |
